Isatuximab for the treatment of multiple myeloma: current clinical advances and future directions.
Saved in:
| Title: | Isatuximab for the treatment of multiple myeloma: current clinical advances and future directions. |
|---|---|
| Authors: | Richardson PG; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., O'Donnell EK; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., O'Gorman P; Haematology Department, The Mater Misericordiae University Hospital, Dublin, Ireland., Leypoldt LB; Department of Hematology, Oncology & Bone Marrow Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Laubach J; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Gay F; Division of Hematology, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy., Leleu X; Department of Hematology, University of Poitiers, CHU & Inserm, Poitiers, France., Facon T; Department of Hematology, University Hospital and INSERM UMR-S1277, Lille, France., Moreau P; Department of Clinical Hematology, University Hospital Hôtel Dieu, Nantes, France., Dimopoulos MA; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.; Department of Medicine, University of Korea, Seoul, South Korea., Goldschmidt H; Heidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany., Mai EK; Heidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany., Cavo M; Department of Surgical and Medical Sciences, Università di Bologna, Bologna, Italy., Weisel KC; Medical Clinic and Polyclinic II, University Hospital Hamburg-Eppendorf, Hamburg, Germany., Berdeja JG; Multiple Myeloma Research, Tennessee Oncology, Nashville, TN, USA., Orlowski RZ; Departments of Lymphoma and Myeloma, and Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Beksaç M; Department of Hematology, Istinye University, Ankara, Turkey., Perrot A; Service d'Hématologie, CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Toulouse, France., Mikhael J; Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, AZ, USA., Martin T; Division of Hematology-Oncology, University of California, San Francisco, CA, USA. |
| Source: | Expert opinion on investigational drugs [Expert Opin Investig Drugs] 2025 Jul-Aug; Vol. 34 (7-8), pp. 571-589. Date of Electronic Publication: 2025 Jul 23. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 9434197 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-7658 (Electronic) Linking ISSN: 13543784 NLM ISO Abbreviation: Expert Opin Investig Drugs Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1744-7658 |
|---|---|
| DOI: | 10.1080/13543784.2025.2532446 |
